BioSpace News Archive

Nordic Nanovector ASA and Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, announce that they have entered into a definitive share exchange agreement to combine the two companies in an all-share transaction.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following investor conferences.

Arcutis Biotherapeutics, Inc., an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.

Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to fifteen new employees to purchase an aggregate of 129,000 ordinary shares under Avadel’s 2021 Inducement Plan.

LianBio (Nasdaq: LIAN) today announced positive topline results from a Phase 2a proof of concept trial evaluating infigratinib in Chinese patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-808, the company’s ROR1 targeting autologous CAR T cell therapy.

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023.

Bioscience Association Manitoba has announced its participation at BIO International Convention, taking place from June 5-8, 2023, at the Boston Convention & Exhibition Center.

Pasithea Therapeutics Corp. confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.